Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($0.80), in-line with the analyst estimate of ($0.80). Revenue for the quarter came in at $7.66 million versus the consensus estimate of $13.18 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.